DE60235097D1 - Verfahren zur induktion einer selektiv unterdrückten immunantwort - Google Patents
Verfahren zur induktion einer selektiv unterdrückten immunantwortInfo
- Publication number
- DE60235097D1 DE60235097D1 DE60235097T DE60235097T DE60235097D1 DE 60235097 D1 DE60235097 D1 DE 60235097D1 DE 60235097 T DE60235097 T DE 60235097T DE 60235097 T DE60235097 T DE 60235097T DE 60235097 D1 DE60235097 D1 DE 60235097D1
- Authority
- DE
- Germany
- Prior art keywords
- cells
- blood
- recipient
- skin
- induce
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000028993 immune response Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000001939 inductive effect Effects 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 210000004369 blood Anatomy 0.000 abstract 3
- 239000008280 blood Substances 0.000 abstract 3
- 210000004443 dendritic cell Anatomy 0.000 abstract 3
- 230000005904 anticancer immunity Effects 0.000 abstract 2
- 230000001640 apoptogenic effect Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000000056 organ Anatomy 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 210000001616 monocyte Anatomy 0.000 abstract 1
- 230000001338 necrotic effect Effects 0.000 abstract 1
- 230000003614 tolerogenic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
- A61M1/3683—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/369—Temperature treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31200401P | 2001-08-13 | 2001-08-13 | |
PCT/US2002/025703 WO2003015850A1 (en) | 2001-08-13 | 2002-08-13 | Method for inducing selectively suppressed immune response |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60235097D1 true DE60235097D1 (de) | 2010-03-04 |
Family
ID=23209429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60235097T Expired - Lifetime DE60235097D1 (de) | 2001-08-13 | 2002-08-13 | Verfahren zur induktion einer selektiv unterdrückten immunantwort |
Country Status (7)
Country | Link |
---|---|
US (2) | US7625557B2 (de) |
EP (1) | EP1427462B1 (de) |
AT (1) | ATE454895T1 (de) |
CA (1) | CA2457015C (de) |
DE (1) | DE60235097D1 (de) |
ES (1) | ES2339752T3 (de) |
WO (1) | WO2003015850A1 (de) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7727523B2 (en) * | 2001-08-13 | 2010-06-01 | Yale University | Method for suppressing immune system response to transplanted tissue or cells |
EP1990055A3 (de) * | 2001-11-29 | 2011-11-16 | Therakos, Inc. | Verfahren zur Vorbehandlung einer Person durch extrakorporale Photopherese und/oder apoptotische Zellen |
AU2004237844B2 (en) * | 2003-12-23 | 2011-01-27 | Therakos, Inc. | Extracorporeal photopheresis in combination with anti-TNF treatment |
AU2013353573B2 (en) | 2012-12-06 | 2019-01-17 | Enlivex Therapeutics R&D Ltd | Therapeutic apoptotic cell preparations, method for producing same and uses thereof |
US20160114095A1 (en) * | 2014-10-27 | 2016-04-28 | Fenwal, Inc. | Methods and systems for collecting mononuclear cells |
GB201513278D0 (en) * | 2015-07-03 | 2015-09-09 | Transimmune Ag And Yale University | Device and method for obtaining immunostimulatory antigen-presenting cells |
NZ746669A (en) * | 2016-04-20 | 2022-10-28 | New Frontier Labs Llc | Azelaic acid esters in the treatment of insulin resistance |
US11679193B2 (en) * | 2017-12-20 | 2023-06-20 | Fenwal, Inc. | System and method of collecting and infusing an apoptotic white blood cell component and a transplant component |
US20220214333A1 (en) * | 2019-04-16 | 2022-07-07 | Regents Of The University Of Minnesota | Biomarker for transplantation tolerance induced by apoptotic donor leukocytes |
WO2023006971A1 (en) * | 2021-07-29 | 2023-02-02 | Transimmune Ag | Selective tolerization - methods of selectively generating tolerogenic dendritic cells |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US66021A (en) | 1867-06-25 | William edwin heath | ||
US4321918A (en) * | 1979-10-23 | 1982-03-30 | Clark Ii William T | Process for suppressing immunity to transplants |
US4683889A (en) | 1983-03-29 | 1987-08-04 | Frederic A. Bourke, Jr. | Method and system for externally treating the blood |
US4838852A (en) * | 1987-03-27 | 1989-06-13 | Therakos, Inc. | Active specific immune suppression |
US5167657A (en) | 1988-11-14 | 1992-12-01 | Baxter International Inc. | Plastic composition with anti-hemolytic effect |
US5147289A (en) | 1990-03-29 | 1992-09-15 | Therakos, Inc | Non-specific immune system enhancement |
DK16393D0 (da) | 1993-02-12 | 1993-02-12 | Silcon Power Electronics As | Noedstroemsanlaeg |
AU2331597A (en) * | 1996-03-22 | 1997-10-10 | Yale University | Methods for inducing immune responsiveness in a subject |
US6194204B1 (en) | 1996-08-02 | 2001-02-27 | Center For Blood Research, Inc. | Enrichment of dendritic cells from blood |
AU2872199A (en) * | 1998-02-20 | 1999-09-06 | Rockefeller University, The | Apoptotic cell-mediated antigen presentation to dendritic cells |
CA2321173A1 (en) * | 1998-03-30 | 1999-10-07 | I.D.M. Immuno-Designed Molecules | Suppressive monocyte derived cells, process for their preparation and their uses in pharmaceutical compositions |
US20050084966A1 (en) | 1999-04-20 | 2005-04-21 | Edelson Richard L. | Methods for inducing the differentiation of blood monocytes into functional dendritic cells |
AU782391B2 (en) * | 1999-04-20 | 2005-07-21 | Richard Leslie Edelson | Differentiation of monocytes into functional dendritic cells |
US6800300B1 (en) * | 2000-03-31 | 2004-10-05 | Vasogen Ireland Limited | Method for treating autoimmune and alloimmune diseases |
CA2309518A1 (en) * | 2000-05-25 | 2001-11-25 | Vasogen Ireland Limited | Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders |
US7727523B2 (en) | 2001-08-13 | 2010-06-01 | Yale University | Method for suppressing immune system response to transplanted tissue or cells |
-
2002
- 2002-08-13 CA CA2457015A patent/CA2457015C/en not_active Expired - Lifetime
- 2002-08-13 WO PCT/US2002/025703 patent/WO2003015850A1/en not_active Application Discontinuation
- 2002-08-13 DE DE60235097T patent/DE60235097D1/de not_active Expired - Lifetime
- 2002-08-13 EP EP02750483A patent/EP1427462B1/de not_active Expired - Lifetime
- 2002-08-13 US US10/217,856 patent/US7625557B2/en not_active Expired - Lifetime
- 2002-08-13 ES ES02750483T patent/ES2339752T3/es not_active Expired - Lifetime
- 2002-08-13 AT AT02750483T patent/ATE454895T1/de not_active IP Right Cessation
-
2009
- 2009-11-30 US US12/627,920 patent/US7988951B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ES2339752T3 (es) | 2010-05-25 |
US7988951B2 (en) | 2011-08-02 |
WO2003015850A1 (en) | 2003-02-27 |
US20100183735A1 (en) | 2010-07-22 |
EP1427462A1 (de) | 2004-06-16 |
CA2457015A1 (en) | 2003-02-27 |
CA2457015C (en) | 2012-03-13 |
US20030059426A1 (en) | 2003-03-27 |
ATE454895T1 (de) | 2010-01-15 |
US7625557B2 (en) | 2009-12-01 |
EP1427462A4 (de) | 2006-06-07 |
EP1427462B1 (de) | 2010-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
von Stebut et al. | Cutaneous leishmaniasis: Distinct functions of dendritic cells and macrophages in the interaction of the host immune system with Leishmania major | |
Bogdan | Natural killer cells in experimental and human leishmaniasis | |
Braun et al. | Mediation of acute but not chronic rejection of MHC-incompatible rat kidney grafts by alloreactive CD4 T cells activated by the direct pathway of sensitization | |
Wang et al. | CD122+ CD8+ Treg suppress vaccine‐induced antitumor immune responses in lymphodepleted mice | |
DE60235097D1 (de) | Verfahren zur induktion einer selektiv unterdrückten immunantwort | |
Liu et al. | Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector | |
AR068984A1 (es) | Proceso para la obtencion de celulas presentadoras de antigenos activados, utiles en las terapias contra el cancer y enfermedades relacionadas del sistema inmunologico | |
EP1810691A3 (de) | Immuntherapie zur Umkehrung einer Immunsuppression | |
Xia et al. | High‐mobility group box 1 accelerates early acute allograft rejection via enhancing IL‐17+ γδ T‐cell response | |
He et al. | Cryo-ablation improves anti-tumor immunity through recovering tumor educated dendritic cells in tumor-draining lymph nodes | |
Vallejo et al. | Cellular pathway (s) of antigen processing in fish APC: effect of varying in vitro temperatures on antigen catabolism | |
Pinheiro et al. | The T-cell anergy induced by Leishmania amazonensis antigens is related with defective antigen presentation and apoptosis | |
MX2022004186A (es) | Composiciones y métodos in vitro para potenciar la activación de células dendríticas y células t, y para inducir una respuesta inmune th-1. | |
Thomson et al. | Tolerogenic dendritic cell-regulatory T-cell interaction and the promotion of transplant tolerance | |
Veltman et al. | Low‐dose cyclophosphamide synergizes with dendritic cell‐based immunotherapy in antitumor activity | |
JP2014516538A5 (de) | ||
NZ507829A (en) | Vaccine adjuvants for immunotherapy of melanoma | |
Kautz‐Neu et al. | Leishmaniasis, contact hypersensitivity and graft‐versus‐host disease: understanding the role of dendritic cell subsets in balancing skin immunity and tolerance | |
Froese et al. | Brief communication: Neuraminidase-induced enhancement of tumor growth in mice | |
DE60329226D1 (de) | Verfahren zur unterdrückung einer immunsystemreaktion gegen gewebe- oder zelltransplantate | |
US20210369774A1 (en) | Micro-rna-155 enhances the efficacy of dendritic cell vaccine for cancer | |
Calderon-Gonzalez et al. | Exceptional antineoplastic activity of a dendritic-cell-targeted vaccine loaded with a Listeria peptide proposed against metastatic melanoma | |
WO2005009397A3 (en) | Human lymphocyte vaccine adjuvant | |
WO2018015815A3 (en) | Plasmodium with histamine releasing factor (hrf) deficiency for use as a vaccine | |
Yin et al. | Antitumor efficacy of argon–helium cryoablation-generated dendritic cell vaccine in glioma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |